Business Context and Reporting Period
This Form 8-K is a current report filed by Anthem, Inc. (now Elevance Health, Inc.) on December 22, 2014. The filing serves as a Regulation FD disclosure to reaffirm the company's financial guidance for the full fiscal year 2014.
Key Financial Metrics
The filing focuses exclusively on earnings per share (EPS) guidance rather than providing a full set of financial statements. Key metrics disclosed include:
- Full Year 2014 Net Income Guidance: $8.83 to $8.93 per share.
- Impact of Favorable Items: The guidance includes $0.08 per share of net favorable items recorded in the first nine months of 2014.
- Adjusted Net Income Guidance: Excluding the favorable items, adjusted net income is expected to be $8.75 to $8.85 per share.
- Investment Gains/Losses: The guidance assumes no additional investment gains or losses beyond those already recorded in the first nine months of 2014.
The filing text does not provide clear values for total revenue, operating profit, cash flow, margins, debt levels, or liquidity ratios.
Material Changes
This report does not disclose material changes to financial results compared to the prior period. Instead, it confirms that the previously issued guidance for the full year 2014 remains unchanged.
Guidance, Outlook, and Risks
Management reaffirmed its outlook for the full year 2014, maintaining the net income per share range of $8.83 to $8.93. The guidance explicitly accounts for specific investment performance assumptions, noting that no further investment gains or losses are anticipated beyond the first nine months. The filing includes standard disclaimers stating that the information is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed explanations of the $0.08 per share favorable items.
- Confirm the company's actual investment portfolio performance for the fourth quarter to validate the assumption of no additional gains or losses.
- Review subsequent filings to determine if the company met the reaffirmed EPS range of $8.83 to $8.93.
- Note that this filing is from the entity then known as Anthem, Inc., which later became Elevance Health, Inc.